Prevention, the highlight of ESC Congress 2009
- Roberto Ferrari, President, European Society of Cardiology and Fausto Pinto, Chairman, Congress Programme Committee
- The AAA study, a randomised controlled trial of low dose aspirin in the prevention of cardiovascular events and death in subjects with asymptomatic atherosclerosis - Gerald Fowkes, Edinburgh
- Childhood obesity: the increasing vascular drama – Sandra Erbs, Leipzig
- CV Prevention in Europe, current challenges and possible solutions – Lars Ryden
Interventional Cardiology
- Unprotected left main revascularization in patients with ACS, the GRACE left main study - Giles Montalescot, Paris
- Randomized trial of 3-Limus agent-eluting stents with biodegradable or permanent polymer coating, the ISAR-TEST-4 study – Julinda Mehili, Munich
- Stent 4 life initiative - Petr Widimsky, Prague
- Safety of DES: Latest data from registries, Stefen James, Uppsala
Heart Failure
- Reduction in the Risk of Heart Failure with Preventive CRT: the MADIT-CRT trial - Arthur Moss, Rochester
- B-CONVINCED, beta-blocker continuation versus interruption in patients with congestive heart failure hospitalized for a decompensation episode – Guillaume Jondeau, Paris
- Effects of rolofylline in patients with acute heart failure syndrome and renal impairment: findings from the PROTECT- Study - Marco Metra, Brescia
ESC Practice guidelines
Clinical trials update
- Effect of ivabradine on cardiovascular outcomes in patients with stable CAD and LV dysfunction with limiting angina: a subgroup analysis of the BEAUTIFUL trial – Roberto Ferrari, Ferrara
- Effect of rosiglitazone on coronary events in the RECORD study - John McMurray, Glasgow
- Optimal revascularization strategy in patients with three-vessel disease and/or left main disease: the 2 year outcomes of the SYNTAX Trial - A Kappetein, Rotterdam
Atrial fibrillation
- RELY, a randomized trial of dabigatran, a oral direct thrombin inhibitor, compared to warfarin in 18,113 patients with atrial fibrillation at high risk of stroke - Stuart Connolly, Hamilton
- Atrial fibrillation – ablation versus treatment ? Josep Brugada, Barcelona
- ACTIVE-I, a randomized evaluation of irbesartan versus placebo in patients with atrial fibrillation – Salim Yusuf, Hamilton
Acute coronary syndrome
- The PLATO trial, a comparison of ticagrelor with clopidogrel in patients with ACS - Lars Wallentin, Uppsala
- CURRENT OASIS 7 Trial: evaluating a high loading and maintenance dose regimen of clopidogrel on major CV events and bleeding in 25,000 patients with ACS – Shamir Mehta, Hamilton
- The Risk of CV event for patients treated with clopidogrel or prasugrel in combination with a proton pump inhibitor: results from the TRITON-TIMI 38 Trial. Michelle O'Donoghue, Boston
|
|